CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that the role of Christopher McNulty has been expanded to include investor relations and corporate communications. Mr. McNulty has been serving as Vice President, Business Development, and will continue to lead efforts in that area.
This move is part of an expanded commitment to InVivo’s outreach to existing investors, new potential institutional investors, the spinal cord injury (SCI) community, and the general public. With a strong management team in place, an on-going first-in-human clinical trial, and a streamlined strategic focus on developing effective therapies for spinal cord injury, InVivo expects to have a steady flow of news over the coming year. Mr. McNulty will lead an integrated corporate communications effort that will include investor relations, public relations, medical/scientific communications, and patient advocacy.
Before coming to InVivo, Mr. McNulty served as Senior Director of Business Development at Repligen Corporation, where his responsibilities included out-licensing programs for rare neurodegenerative diseases. Previously, he was Director of Corporate Development at Seventh Sense Biosystems and Associate Director of Business Development and Alliance Management at Genzyme Corporation. Mr. McNulty has also held technical roles at Transform Pharmaceuticals and Cereon Genomics. He has an MBA from Harvard Business School, and BS and MEng degrees from MIT.
Mark Perrin, InVivo’s Chief Executive Officer, said, “Combining our investor relations, public relations, medical communications, and patient advocacy efforts into a comprehensive and synergistic corporate communications function will improve our communication efforts to all our constituents. We have engaged excellent partners with expertise in each of these areas to assist us in our efforts, and I look forward to our future activities.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011 the Company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit, www.invivotherapeutics.com.